Recurrent Ovarian Cancer — Sculpting a Promising Future with Surgery

This article is an editorial discussing recent randomized trials evaluating secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer, particularly the DESKTOP III trial. It highlights how complete gross resection during secondary surgery improves survival outcomes. The authors emphasize the importance of careful patient selection criteria, surgical quality, and integration with targeted therapies. They advocate for using both surgical and molecular tools to optimize personalized treatment and move toward curative strategies in ovarian cancer.

This article is an editorial discussing recent randomized trials evaluating secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer, particularly the DESKTOP III trial. It highlights how complete gross resection during secondary surgery improves survival outcomes. The authors emphasize the importance of careful patient selection criteria, surgical quality, and integration with targeted therapies. They advocate for using both surgical and molecular tools to optimize personalized treatment and move toward curative strategies in ovarian cancer.